Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing

Citation
D. Cilloni et al., Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing, BONE MAR TR, 23(5), 1999, pp. 497-503
Citations number
36
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Journal title
BONE MARROW TRANSPLANTATION
ISSN journal
02683369 → ACNP
Volume
23
Issue
5
Year of publication
1999
Pages
497 - 503
Database
ISI
SICI code
0268-3369(199903)23:5<497:PHPWMB>2.0.ZU;2-K
Abstract
Uncontrolled-rate freezing techniques represent an attractive alternative t o controlled-rate cryopreservation procedures which are time-consuming and require high-level technical expertise. In this study, we report our experi ence using uncontrolled-rate cryopreservation and mechanical freezer storag e at -140 degrees C. Twenty-eight PBPC samples (10 cryovials, 18 freezing b ags) from 23 patients were cryopreserved in a cryoprotectant solution compo sed of phosphate-buffered saline (80%, v/v) supplemented with human serum a lbumin (10%, v/v) and dimethylsulfoxide (10%, v/v). The cryopreservation pr ocedure required on average 1.5 h. The mean (+/- s.e.m.) storage time of cr yovials and bags was 344 +/- 40 and 299 +/- 57 days, respectively. Although cell thawing was associated with a statistically significant reduction of the absolute number of nucleated cells (vials: 0.3 x 10(9) vs 0.2 x 10(9), P less than or equal to 0.02; bags: 14 x 10(9) vs 11 x 10(9), P < 0.0003), the growth of committed progenitors was substantially unaffected by the fre ezing-thawing procedure, with mean recoveries of CFU-Mix, BFU-E, and CFU-GM ranging from 60 +/- 29% to 134 +/- 15%. Mean recoveries of LTC-IC from cry ovials and bags were 262 +/- 101% and 155 +/- 27% (P less than or equal to 0.2), respectively. In 14 out of 23 patients who underwent high-dose chemot herapy and PBPC reinfusion, the pre- and post-freezing absolute numbers of hematopoietic progenitors cryopreserved in bags were compared. A significan t reduction aas detected for CFU-Mix (11 vs 7.4 x 10(5)), but no significan t loss of BFU-E (180 vs 150 x 10(5)), CFU-GM (400 vs 290 x 10(5)) and LTC-I C (15 vs 16 x 10(5)) could be demonstrated. When these patients were reinfu sed with uncontrolled-rate cryopreserved PBPC, the mean number of days to r each 1 x 10(9)/l white blood cells and 50 x 10(9)/l platelets were 9 and 13 , respectively. In conclusion, the procedure described here is characterize d by short execution time, allows a substantial recovery of primitive and c ommitted progenitors and is associated with prompt hematopoietic recovery f ollowing myeloablative therapy even after long-term storage.